Research Articles
Cruisin’ for a Bruisin’
2020-03-18
Introduction I do believe that investors need to be cognizant of the fact that what is happening today is not the norm with stock markets. Instead, I’d like to point out that the risk we are facing right now is what I call an event risk. This is something unforeseen that comes along every so […]
The Dow Jones – How Bad Is It?
2020-03-17
Introduction The Dow Jones Industrial Average is an index of 30 stocks that is often utilized as a proxy for the overall market. Since it is such a small index, I thought you all might find it interesting to see what the market looks like considering the recent volatility. Therefore, with this video I will […]
Top 10 Dividend Aristocrats to Buy In This Crazy Market
2020-03-11
Introduction For those investors interested in investing for an increasing dividend income stream, the Dividend Aristocrats to buy represent the crème de la crème. Standard & Poor’s produces this premier list of blue-chip dividend growth stocks that have increased their dividends for 25 consecutive years. Given the quality and blue-chip status of this group of […]
Recent Market Action A Value Investor’s Perspective
2020-03-05
Introduction For some time now I have been pointing out that the stock market as measured by the S&P 500 has become moderately overvalued. However, even more to the point, I still believe that to be true even after the price corrections we have experienced recently as a result of the coronavirus. In other words, […]
Tesla: Do the Fundamental Support the Stock Price?
2020-02-26
Introduction I have been asked to provide a FAST Graph analyze out loud video on Tesla (TLSA) from many subscribers to our YouTube channel. This is a difficult company to analyze based on fundamentals. In some sense, it is really a tale of two companies. The first story refers to the company fundamentals from the […]
Is the New Pfizer an Attractive Investment?
2020-02-25
Introduction Pharmaceutical giant Pfizer (PFE) is a company in transition that will soon be smaller but hopefully more profitable. Since many of their established drugs are coming off patent, the company is divesting its older drug platform under the Upjohn brand and selling it to Mylan a leading generic pharmaceutical company. Pfizer believes that this […]